The CEASE-AF trial highlights Hybrid ablation’s impressive long-term durability, showing a ~33% improvement in freedom from atrial arrhythmias* over 24 months for patients with long-standing persistent Afib**. Learn more about the compelling data behind Hybrid AF™ Therapy at <a href='https://www.linkedin.com/feed/hashtag/?keywords=AHA2024.&highlightedUpd…; target='_blank'>#AHA2024.</a>
In the meantime, explore further here: <a href="https://okt.to/qy0uc3" target="_blank">https://okt.to/qy0uc3</a>
*Freedom from atrial arrhythmias (atrial fibrillation, atrial flutter, atrial tachycardia) off anti-arrhythmic drugs (AADs) except previously failed AADs at doses not exceeding those previously failed
**Persistent atrial fibrillation with enlarged left atrium and longstanding persistent Afib
- Healthcare Professionals
- Therapies and Procedures
- Concomitant Surgical Ablation Therapy
- Ablation Sensing Unit & Switch Matrix
- cryoFORM® Cryoablation Probe
- cryoICE® BOX V6
- cryoICE® Cryoablation Probes
- Isolator® Linear Pen
- Isolator® Synergy™ Access® Clamp
- Isolator® Synergy™ Clamps (OLL2/OSL2)
- Isolator® Transpolar Pen (MAX3)
- Isolator® Synergy™ EnCompass® Clamp
- Multifunctional Ablation Generator (MAG)
- Hybrid AF™ Therapy
- Hybrid Total Thoracoscopic Therapy
- Left Atrial Appendage Management
- Cryo Nerve Block Therapy
- Concomitant Surgical Ablation Therapy
- Education & Training
- Clinical Evidence
- Product Labeling
- Resources
- Society Guidelines
- Therapies and Procedures
- Patients & Caregivers
- About AtriCure
